4D Molecular Therapeutics (FDMT) Selling, General & Administrative (2020 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Selling, General & Administrative (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 582.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 662.10 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -417.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 216.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 110.21 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 593.21 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 161.89 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 247.47 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 686.42 Mn | - | 12.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.52 Mn |
| Mar 31, 2026 | 11.69 Mn |
| Dec 31, 2025 | 12.77 Mn |
| Sep 30, 2025 | 11.84 Mn |
| Jun 30, 2025 | 11.52 Mn |
| Mar 31, 2025 | 12.94 Mn |
| Dec 31, 2024 | 13.03 Mn |
| Sep 30, 2024 | 12.65 Mn |
| Jun 30, 2024 | 10.60 Mn |
| Mar 31, 2024 | 10.29 Mn |
| Dec 31, 2023 | 10.61 Mn |
| Sep 30, 2023 | 9.11 Mn |
| Jun 30, 2023 | 8.79 Mn |
| Mar 31, 2023 | 7.99 Mn |
| Dec 31, 2022 | 8.47 Mn |
| Sep 30, 2022 | 8.06 Mn |
| Jun 30, 2022 | 8.17 Mn |
| Mar 31, 2022 | 8.23 Mn |
| Dec 31, 2021 | 7.33 Mn |
| Sep 30, 2021 | 8.19 Mn |